Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 1998

View Archived Issues

B43-PAP: a promising treatment for Ph+ ALL in development at Hughes Institute

Shire: nine-month 1998 highlights

Novo Nordisk: nine-month 1998 highlights

Ligand: Q3 1998 highlights

Nortran announces positive phase II trial results with RSD-921

OraVax files IND for colitis vaccine

Company Profile: Cetek

GlycoDesign expands phase II cancer trial with GD0039

Cell Genesys broadens GVAX trials program in prostate cancer

Neurocrine Biosciences advances development of NBI-3001

Inex receives patent protection for vital component of TCS delivery system

Transkaryotic Therapies extends agreement with PolyMASC to include second drug candidate

Multiple clinical studies support efficacy and safety of HSR-237 in patients with IBS

International study focuses on riluzole as a new approach to treating PD

New market introductions for raloxifene

SSRI promising in the treatment of children and adolescents with OCD

Unimed receives U.S. patent protection for dronabinol in treatment of dementia

FDA advisory committee meets this week to discuss Celebrex NDA

LTA4 hydrolase inhibitors reported in development at Santen

Antimicrobial and antitumor activity of xenomin compounds described

Shionogi claims new agents for influenza

TAK-778: candidate for development in the treatment of osteoporosis

Banyu reports success in the search for new ACAT inhibitors

Fujisawa discovers V-ATPase inhibitor with potential for treating osteoporosis

Alkermes, Schering-Plough agree to terminate collaboration

Guilford presents two new series of NAALADase inhibitors

Australian team demonstrates safety of diabetes vaccine in patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...